Ji Min Lee

Pseudomyxoma peritonei (PMP) of appendiceal origin presents a unique challenge in oncology owing to its rarity, varied progression, and complex molecular characteristics. The current standard treatment using cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy has shown some success in extending survival rates; however, it is associated with significant physical burdens and high recurrence rates. Advances in understanding the molecular and genetic features, particularly mutations in genes such as KRAS, GNAS, and BRAF, have led to a promising shift toward more targeted and less invasive treatment options, potentially moving beyond the limitations of current therapies. Additionally, novel approaches targeting the tumor microenvironment in PMP have gained traction, given the role of factors such as mucin accumulation, hypoxia, and inflammatory cytokines in sustaining tumor persistence and resistance. Emerging personalized therapies and immunotherapies, particularly targeted treatments and peptide vaccine development for GNAS-mutated cancers, offer the potential to enhance treatment specificity and effectiveness. The challenges of multiomics approaches to capture the complex genomic and epigenomic landscape of PMP highlight the need for individualized optimal treatment in patients with PMP.

Characterization of integrin αv regulation in TECs and EC progenitors

List of stage-specific cCREs across vascular EC development from hESCs

List of stage-specific genes across vascular EC development from hESCs

Transcriptomic landscape profiling of hESC-EC differentiation

List of TEC-specific cCREs across vascular EC subtypes from colorectal tumors

H3K27ac landscape profiling of hESC-EC differentiation

Evaluation of genome-wide 3D chromatin contact profiles of vascular EC progenitors

List of TEC-specific genes across vascular EC subtypes from cross-cancer scRNA-seq data

Identification of TEC-specific gene expression and its association with clinical outcomes